Bill
Bill > HB3174
OK HB3174
Public health; providing for the establishment of statewide investigational new drug applications for psilocybin clinical trials; effective date.
summary
Introduced
02/07/2022
02/07/2022
In Committee
02/08/2022
02/08/2022
Crossed Over
Passed
Dead
05/27/2022
05/27/2022
Introduced Session
2022 Regular Session
Bill Summary
An Act relating to public health; defining terms; providing for the establishment of statewide investigational new drug applications for psilocybin clinical trials; authorizing physicians to serve as principal investigators for clinical trials under certain circumstances; providing for subinvestigators; directing investigators and subinvestigators to adhere to certain rules and regulations; permitting Oklahoma State Bureau of Narcotics and Dangerous Drugs Control to inspect certain samples; providing guidelines for conducting clinical trials; exempting person acting in compliance from criminal or civil penalties; permitting State Commissioner of Health to perform certain acts; requiring clinical trials to comply with certain standards; providing termination date; requiring certain approval for continuation of clinical trials; requiring submission of certain report; specifying contents of report; authorizing Commissioner to disclose certain data; directing promulgation of rules by certain entities; providing for codification; and providing an effective date.
AI Summary
This bill establishes a statewide investigational new drug application in Oklahoma to conduct clinical trials using psilocybin, a hallucinogenic compound, on qualifying patients who are veterans suffering from major depressive disorder, severe depression, or other forms of depression or anxiety not adequately treated by traditional therapies. The bill allows licensed physicians in Oklahoma to serve as principal investigators for these trials if they meet certain requirements, such as obtaining approval from the FDA and licenses from the DEA and Oklahoma's narcotics bureau. The trials must adhere to strict standards and regulations, and the State Commissioner of Health has oversight authority, including the ability to terminate trials for substantial violations. The bill also requires the Commissioner to submit a report on the trial findings and allows for the disclosure of certain data related to the trials.
Sponsors (2)
Last Action
Second Reading referred to Rules (on 02/08/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | http://www.oklegislature.gov/BillInfo.aspx?Bill=hb3174&Session=2200 |
| BillText | http://webserver1.lsb.state.ok.us/cf_pdf/2021-22%20INT/hB/HB3174%20INT.PDF |
Loading...